Deep-Coverage Ubiquitylomics with Low Starting Materials Reveals Dysregulation of Ubiquitinated FASN as a Key Regulator of MAFLD Pathogenesis

Deep-Coverage Ubiquitylomics with Low Starting Materials Reveals Dysregulation of Ubiquitinated FASN as a Key Regulator of MAFLD Pathogenesis

Metabolic-associated fatty liver disease (MAFLD), characterized by excessive hepatic lipid deposition, poses a global health threat, increasing the risk of severe liver complications. Here, we optimized a <b>f</b>ast <b>i</b>n-<b>t</b>ube <b>m</b>icros...

Full description

Saved in:

Bibliographic Details
Main Author:	Bendong Yang (11074740) (author)
Other Authors:	Jinfang Liu (6630542) (author), Hongtao Wen (11460187) (author), Yanchang Li (696755) (author), Ruixi Liu (2558827) (author), Yuping Xie (445029) (author), Bin Fu (1480723) (author), Guibin Wang (369042) (author), Ping Xu (122619) (author)
Published:	2025
Subjects:	Biophysics Biochemistry Cell Biology Genetics Molecular Biology Neuroscience Immunology Cancer Inorganic Chemistry Virology Computational Biology Chemical Sciences not elsewhere classified Information Systems not elsewhere classified western blot analysis severe liver complications novel regulatory axis liver tissue samples ketosynthase family 3 global health threat fatty acid synthase elevated protein level developing targeted diagnostic dependent protein stabilization mafld ), characterized combat mafld progression fatty acid metabolism n -< b 7384 ubiquitinated peptides overall ubiquitination density fasn protein exhibits entire fasn protein dysregulated ubiquitination network mafld pathogenesis metabolic ubi </ b f </ b mfas dh domain </ b mafld research mafld model ubiquitinated fasn metabolic dysregulation ubiquitinated proteins unveiling ubiquitination typical features therapeutic strategies study explored significantly enriched requiring less quitylomics strategy paradoxical accumulation ms data microscale ubiquitylomics lipid metabolism key regulator even lower coverage ubiquitylomics bioinformatics analyses 6 %). 28 %, 25 %. 10 mg
Tags:	Add Tag No Tags, Be the first to tag this record!

Cannot write session to /tmp/vufind_sessions/sess_d0agaq1mog3n6s2t3adfhnekj3